Hepatic Fibrosis Biomarkers Market (2025 - 2033)

Hepatic Fibrosis Biomarkers Market Summary

The global hepatic fibrosis biomarkers market size was estimated at USD 423.51 million in 2024 and is projected to reach USD 2,291.73 million by 2033, growing at a CAGR of 20.01% from 2025 to 2033. The rising prevalence of NASH, a consequence of obesity, sedentary lifestyles, and metabolic syndrome, has led to a greater focus on hepatic fibrosis biomarkers.

According to the study published in the National Institutes of Diabetes and Digestive and Kidney Diseases, NAFLD affects one-third to two-thirds of individuals with type 2 diabetes. Studies also indicate that over 90% of individuals with extreme obesity and up to 75% of overweight individuals have NAFLD. One of the key drivers propelling the demand for NASH-specific hepatic fibrosis biomarkers is the clinical significance of fibrosis staging. The risks and limitations associated with liver biopsies and non-invasive biomarkers offer a safer and more patient-friendly approach to monitoring hepatic fibrosis progression in NASH patients.

As of the most recent estimates, approximately 3.3% of the global population is living with advanced hepatic fibrosis, with rates rising to around 3.5% when measured using vibration-controlled transient elastography (VCTE). Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), affects about 25% of the world’s population, with prevalence increasing to 38% in certain regions between 2016 and 2019 due to rising obesity and type 2 diabetes rates.

The adoption of tests such as ELF, FIB-4, NAFLD fibrosis score, APRI, and FibroTest/FibroSure, alongside emerging multi-marker panels like IGFBP7/SSc5D/Sema4D, is enabling earlier detection, accurate staging, and reduced reliance on invasive liver biopsies. These advancements, combined with rising screening initiatives, are positioning hepatic fibrosis biomarkers as a central tool in tackling the global liver disease epidemic.

The dynamics of liver fibrosis are specifically targeted by noninvasive biomarkers of liver condition, such as NASH, which offer a novel tool to assess a patient's disease progression. Such indicators for liver illness could be applied to patient risk classification as well as prognostic enrichment of clinical trials aimed at the individuals with the highest risk, improving the likelihood of success. These blood biomarkers are also accurate indicators of the dynamics of liver fibrosis and can be used to gauge the success of a given treatment. Nordic Bioscience NASH specialists can examine a precise panel of liver fibrosis biomarkers, including the biomarker PRO-C3 NASH, which offers insight into the course of the illness.

In addition to these advancements, GENFIT unveiled NASHnext, an innovative, noninvasive diagnostic test driven by GENFIT's NIS4 Technology. This test, exclusively available in the U.S. and Canada through LabCorp, a global leader in life sciences, harnesses a unique blood-based molecular biomarker test to identify individuals with at-risk NASH who possess at least one metabolic risk factor. This breakthrough enhances the diagnostic & prognostic capabilities of NASH patients, offering a promising avenue for improved disease management and clinical trial success.

Several chronic diseases are associated with NAFLD/NASH. The associated conditions are illustrated below:

Moreover, as per the International Diabetes Federation, the estimated prevalence of diabetes in 2019 was 9.3%, representing 463 million people globally, and this percentage is likely to reach 10.2% by 2030. The prevalence of diabetes is very high in India. Even in Japan and China, the prevalence of cancer and diabetes has increased over the past years.

The table below highlights the prevalence of diabetes in the age group of 20 to 79 years:

Prevalence of diabetes in 2021, 2030, and 2045

Source: International Diabetes Federation 2021, Grand View Research

In addition, NASH has emerged as a major public health concern worldwide, closely linked to obesity, diabetes, and metabolic syndrome. According to recent data from the Global Liver Institute, NASH affects an estimated 115 million people globally, with numbers steadily increasing. This prevalence is driven by the growing prevalence of obesity and type 2 diabetes, both of which are significant risk factors for NASH development. As a result, the demand for effective diagnostic tools like biomarkers to detect NASH early and accurately is surging.

Prevalence of NASH worldwide and by ethnicity:

Market Concentration & Characteristics

The hepatic fibrosis biomarkers industry is characterized by a steady pace of innovation, particularly in transitioning from invasive liver biopsy to non-invasive diagnostic tools. Novel biomarker panels combining serum-based indicators with imaging modalities are entering clinical practice. In September 2023, the Foundation for the National Institutes of Health (FNIH) revealed research results published in Nature Medicine that showcase the efficacy of noninvasive blood tests for diagnosing NASH. This breakthrough represents a significant step towards obtaining approval from the U.S. Food and Drug Administration (FDA). The study findings originate from the FNIH’s Biomarkers Consortium, which is dedicated to validating and qualifying biomarkers to expedite the development of new treatments and healthcare technologies through collaborative efforts across various sectors.

Mergers and acquisitions in this space are driven by the need to consolidate technology portfolios and expand regional reach. Meridian Bioscience’s acquisition of Exalenz Bioscience brought advanced breath-testing technology that complements fibrosis biomarker portfolios. Strategic deals between diagnostics companies and contract research organizations (CROs) are also being observed to embed biomarkers into pharmaceutical development workflows, particularly for NASH and MASLD drug trials.

Regulatory agencies are increasingly supportive of non-invasive fibrosis diagnostics as adjuncts or replacements for biopsy in specific clinical contexts. The U.S. FDA and European regulatory bodies have cleared several biomarker tests, such as the Enhanced Liver Fibrosis (ELF) test, for clinical use. In Asia, regulatory adoption varies-Japan and China are gradually formalizing approval pathways for advanced biomarker panels. The inclusion of non-invasive fibrosis assessment in EASL, AASLD, and APASL guidelines further accelerates market acceptance.

Manufacturers are diversifying their portfolios beyond single biomarkers to multi-marker panels and integrating them with imaging-based solutions (e.g., FibroScan). Quest Diagnostics and Labcorp have expanded their hepatic fibrosis test menus within their clinical lab offerings, while biotech firms like GENFIT are moving towards companion diagnostics aligned with emerging antifibrotic therapies. Point-of-care assay development remains a niche but promising segment, especially for resource-limited settings.

Global players are actively strengthening their footprint in Asia Pacific, Latin America, and the Middle East & Africa through partnerships with local labs and distributors. Siemens Healthineers and BioPredictive have increased distribution in China and India, while Quest Diagnostics has expanded operations in Brazil and Mexico. Companies are also targeting Gulf countries due to high obesity-related liver disease prevalence and rising healthcare investments.

Product Insights

The kits and reagent segment led the market with the largest revenue share of 48.04% in 2024. Kits such as BioPredictive’s FibroTest and GENFIT’s NIS4 panel have set benchmarks for non-invasive liver fibrosis detection, offering reproducibility and compatibility with high-throughput analyzers. Continuous launches of specialized kits targeting NASH, hepatitis B/C, and alcohol-related liver disease are expanding the application base. For example, new ELISA-based fibrosis detection kits introduced in Asia-Pacific markets in 2024 have accelerated adoption in secondary care facilities. The recurring demand for reagents in existing test platforms ensures a stable revenue stream for both multinational and regional players, particularly in markets with growing screening programs.

The assays segment is anticipated to grow at the fastest CAGR during the forecast period. Portable fibrosis biomarker devices, including microfluidics-enabled cartridges and rapid immunochromatographic assays, are being introduced in community clinics and rural health settings. These innovations are especially impactful in Asia-Pacific and Latin America, where centralized laboratory access is limited. Recent POC assay launches by Exalenz Bioscience (Meridian Bioscience), integrated with breath-test-based liver function analytics, have expanded non-invasive fibrosis screening to primary care levels. This decentralization trend not only increases early diagnosis rates but also reduces patient burden from invasive procedures like liver biopsy.

Technology Insights

The immunoassay segment accounted for the largest market revenue share in 2024. This is due to its proven analytical accuracy, scalability for high-throughput screening, and ability to measure multiple biomarkers from small serum volumes. Chemiluminescent and enzyme-linked immunosorbent assay (ELISA) formats remain the industry standard, while electrochemiluminescent platforms are being deployed for improved sensitivity. Global players like Siemens Healthineers continue to enhance immunoassay analyzers with liver disease panels integrated into broader metabolic screening platforms. Additionally, new automated immunoassay systems launched in 2024 in Japan and China have further lowered turnaround times, supporting faster treatment initiation.

The molecular diagnostics segment is expected to grow at the fastest CAGR during the forecast period, driven by the application of genomic, transcriptomic, and proteomic signatures for precision medicine approaches in hepatic disease management. RNA-based assays for fibrosis staging, now in pilot use across academic research institutes in Europe and Asia, are expected to see broader clinical uptake in the next five years. However, higher per-test costs and infrastructure requirements limit their penetration outside major urban centers.

End Use Insights

The hospitals segment led the market with the largest revenue share of 38.09% in 2024 and is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the high patient volume for chronic liver diseases, the availability of advanced diagnostic infrastructure, and the integration of biomarker testing into standard hepatology and gastroenterology care pathways. Tertiary care and teaching hospitals, particularly in countries with universal healthcare coverage, are incorporating non-invasive fibrosis biomarkers into their liver disease management protocols, reducing reliance on invasive liver biopsies.

The specialty clinics segment is expected to grow at a significant CAGR over the forecast period, fueled by the rising number of hepatology and gastroenterology centers offering targeted liver disease management programs. These clinics are early adopters of novel biomarker assays, including point-of-care (POC) fibrosis tests and advanced biomarker panels, which enable faster staging of fibrosis and monitoring of treatment response. In regions with limited hospital infrastructure, specialty clinics are emerging as primary diagnostic hubs, often partnering with biotechnology firms like GENFIT and BioPredictive to pilot new test kits.

Regional Insights

North America dominated the hepatic fibrosis biomarkers market with the largest revenue share of 48.87% in 2024, driven by increasing obesity and metabolic syndrome prevalence, spurring demand for non-invasive diagnostic tools that can stage fibrosis without a biopsy. Recent cost-effectiveness analyses and practice guidance from AASLD/AACE reinforce two-step screening in primary care and endocrinology/diabetes cohorts, where MASLD risk is high. In the U.S.-Mexico border region and other high-risk primary-care settings, studies highlight the large undiagnosed pool that can be triaged with FIB-4 and advanced with serologic panels (ELF, PRO-C3/PROC3, and proprietary composites).

U.S. Hepatic Fibrosis Biomarkers Market Trends

The hepatic fibrosis biomarkers market in the U.S. is growing due to the rising prevalence of obesity, type 2 diabetes, and metabolic syndrome has led to a significant increase in the incidence of non-alcoholic steatohepatitis (NASH) in the U.S. According to the National Institutes of Diabetes and Digestive and Kidney Diseases, non-alcoholic fatty liver disease (NAFLD) affects up to 24% of U.S. adults, and NASH is estimated to affect 1.5% to 6.5% of the U.S. population. As the prevalence of NAFLD and NASH continues to rise, there is a greater need for diagnostic tests and treatments, driving the demand for NASH biomarkers. Further, the development of biomarker tests by major corporations is expected to drive the NASH biomarkers market over the forecast period. For instance, in May 2021, GENFIT and Laboratory Corporation of America Holdings launched NASHnext in the U.S. and Canada, a non-invasive NASH detection test powered by NIS4 technology for use in the clinic.

Europe Hepatic Fibrosis Biomarkers Market Trends

The hepatic fibrosis biomarkers market in Europe is experiencing strong growth. Europe’s diagnostics market benefits from strong society guidance and structured care pathways. EASL’s 2024 clinical practice direction emphasizes non-invasive testing strategies, and industry updates in mid-2024 highlighted NIS2+ (GENFIT’s optimized blood-based panel) as a key tool for detecting at-risk disease-supporting broader adoption of laboratory biomarkers alongside routine indices and elastography. Multiple European real-world studies in 2024 demonstrated sequential algorithms (automatic FIB-4 in primary care followed by ELF ≥9.8) efficiently identify advanced fibrosis while minimizing unnecessary biopsies and referrals; parallel work from Scandinavia found FIB-4→ELF pathways cost-efficient and practical for population triage.

The UK hepatic fibrosis biomarkers market is growing rapidly. In the UK, NHS pathway design and real-world evaluations are propelling blood-based fibrosis testing beyond specialist clinics. The intelligent Liver Function Testing (iLFT) pathway evaluated in 2024 showed how automated lab rules can escalate from routine LFTs to targeted non-invasive tests, improving case-finding and referral quality in everyday practice. PMC In 2025, a UK primary-care study in BMJ Open Gastroenterology found that deploying ELF in community settings facilitated earlier diagnosis and streamlined stratification-an outcome aligned with NHS priorities to reduce unnecessary biopsy and specialty bottlenecks

Asia Pacific Hepatic Fibrosis Biomarkers Market Trends

The hepatic fibrosis biomarkers market in Asia Pacific is growing rapidly, supported by a high and rising prevalence of chronic liver diseases linked to hepatitis B and C infections, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). Countries such as China, Japan, India, and South Korea are witnessing increased screening initiatives and clinical adoption of non-invasive diagnostic tools. Key players, including Siemens Healthineers with its ELF test and Roche’s collaborations in the region, are driving adoption through local partnerships and analyzer placements. The presence of global diagnostics firms alongside regional laboratories is boosting accessibility. Market opportunities lie in expanding early detection programs, integrating biomarker testing into diabetic and obesity clinics, and tapping into growing pharmaceutical clinical trial demand for NASH and MASLD therapies.

The Japan hepatic fibrosis biomarkers market is gradually embracing hepatic fibrosis biomarkers, with growth supported by its aging population and high prevalence of hepatitis C-related liver damage, as well as increasing cases of MASLD. Japanese clinical guidelines are progressively recognizing the value of non-invasive fibrosis assessment, driving interest in biomarker-based panels such as ELF and FibroTest. GENFIT and local distributors are exploring strategic collaborations to introduce advanced biomarker platforms, while academic research institutions in Japan are contributing to biomarker validation studies. Opportunities exist in aligning biomarker adoption with Japan’s preventive healthcare model and national screening programs, particularly in hepatology and metabolic clinics.

The hepatic fibrosis biomarkers market in China is expanding rapidly, driven by a large patient base with chronic hepatitis B, growing rates of fatty liver disease linked to lifestyle changes, and increasing awareness of early fibrosis detection. The government’s emphasis on reducing the burden of advanced liver disease is opening pathways for biomarker inclusion in public health screening. Siemens Healthineers and BioPredictive are actively collaborating with Chinese laboratories and diagnostic chains to make non-invasive panels more available. With pharmaceutical companies like AstraZeneca and Pfizer conducting liver disease trials in China, there is also a significant opportunity for biomarkers to be embedded in patient selection and monitoring protocols.

Latin America Hepatic Fibrosis Biomarkers Market Trends

The hepatic fibrosis biomarkers market in Latin America is experiencing moderate to high growth in hepatic fibrosis biomarkers, propelled by the dual burden of viral hepatitis and rising MASLD prevalence due to obesity and diabetes. Countries such as Brazil, Mexico, and Argentina are gradually incorporating non-invasive fibrosis tests into clinical pathways to reduce dependence on liver biopsy. Companies like Quest Diagnostics and Labcorp are expanding their reference laboratory capabilities in the region, enabling access to advanced fibrosis testing without the need for international sample shipping. There is untapped potential in aligning biomarker testing with national hepatitis elimination programs and leveraging partnerships with local healthcare providers to broaden patient reach.

Middle East and Africa Hepatic Fibrosis Biomarkers Market Trends

The hepatic fibrosis biomarkers market in the Middle East and Africa region shows strong potential for hepatic fibrosis biomarkers growth, primarily driven by high rates of obesity, type 2 diabetes, and hepatitis infections in Gulf countries and parts of Africa. Increasing investment in healthcare infrastructure, particularly in the UAE, Saudi Arabia, and South Africa, is facilitating the introduction of advanced diagnostics. Key players such as Siemens Healthineers and Exalenz Bioscience (Meridian Bioscience) are positioning non-invasive fibrosis solutions in tertiary hospitals and specialty clinics. Opportunities exist in integrating biomarkers into national metabolic disease screening programs, as well as in supporting pharmaceutical trials for liver disease therapies targeting high-prevalence populations.

Key Hepatic Fibrosis Biomarkers Company Insights

The hepatic fibrosis biomarkers industry is driven by a mix of established diagnostics companies and specialized innovators focused on expanding access and ease of testing. Major players shaping this landscape include GENFIT, known for its NIS4 and upgraded NIS2+ multi-marker panels, Prometheus Laboratories, Siemens Healthineers (via the ELF test), BioPredictive (FibroTest/ActiTest), Quest Diagnostics, Labcorp, as well as pharmaceutical innovators such as AstraZeneca, Pfizer, Bristol-Myers Squibb, and Exalenz Bioscience (Meridian Bioscience).

Recent Developments

• In March 2025, Precision BioSciences received FDA clearance (IND approval) for its lead candidate PBGENE-HBV, marking it as the first-ever in vivo gene-editing therapy to enter clinical trials in the United States for chronic hepatitis B. PBGENE-HBV uses ARCUS meganuclease delivered via lipid nanoparticles to eliminate the viral reservoirs cccDNA and integrated HBV DNA, aiming for a functional cure.

• In November 2024, Arbutus Biopharma and Barinthus Bio jointly announced new interim data from the IM-PROVE II Phase 2a clinical trial in chronic hepatitis B. The combination of VTP-300, low-dose nivolumab, and imdusiran demonstrated increased rates of HBsAg loss, indicating enhanced therapeutic potential toward achieving a functional cure. These results reinforce the value of combining immune modulators with RNA-targeted therapies in treating chronic HBV.

• In June 2022, Echosens entered into a partnership with Novo Nordisk A/S for advancement in early diagnosis of NASH and increasing awareness among healthcare providers, patients, and other stakeholders about the condition.

Hepatic Fibrosis Biomarkers Market